ATE411037T1 - Diagnose und behandlung von tumor-suppressor assoziierten krankheiten - Google Patents

Diagnose und behandlung von tumor-suppressor assoziierten krankheiten

Info

Publication number
ATE411037T1
ATE411037T1 AT01965965T AT01965965T ATE411037T1 AT E411037 T1 ATE411037 T1 AT E411037T1 AT 01965965 T AT01965965 T AT 01965965T AT 01965965 T AT01965965 T AT 01965965T AT E411037 T1 ATE411037 T1 AT E411037T1
Authority
AT
Austria
Prior art keywords
tslc1
expression
disorder
proliferating
reagent
Prior art date
Application number
AT01965965T
Other languages
English (en)
Inventor
Roger Reeves
Yoshinori Murakami
Original Assignee
Univ Johns Hopkins Med
Nat Cancer Ct Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Nat Cancer Ct Res Inst filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE411037T1 publication Critical patent/ATE411037T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT01965965T 2000-08-15 2001-08-15 Diagnose und behandlung von tumor-suppressor assoziierten krankheiten ATE411037T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22526400P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
ATE411037T1 true ATE411037T1 (de) 2008-10-15

Family

ID=22844210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01965965T ATE411037T1 (de) 2000-08-15 2001-08-15 Diagnose und behandlung von tumor-suppressor assoziierten krankheiten

Country Status (7)

Country Link
US (3) US6596493B1 (de)
EP (1) EP1339871B1 (de)
AT (1) ATE411037T1 (de)
AU (1) AU2001286514A1 (de)
CA (1) CA2419529C (de)
DE (1) DE60136212D1 (de)
WO (1) WO2002014557A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136212D1 (de) * 2000-08-15 2008-11-27 Univ Johns Hopkins Med Diagnose und behandlung von tumor-suppressor assoziierten krankheiten
DE60318294T2 (de) * 2003-03-31 2008-12-11 Stichting Researchfonds Pathologie Nachweis von invasivem Krebs induziert von HPV und dessen Vorläufer Läsionen mit Invasionspotential
WO2005012530A2 (en) * 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use
JP4942644B2 (ja) * 2005-02-28 2012-05-30 株式会社抗体研究所 抗ＩｇＳＦ４抗体及びその利用
ES2625259T3 (es) * 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
TWI335354B (en) 2006-09-27 2011-01-01 Univ Hong Kong Chinese Methods for the detection of the degree of the methylation of a target dna and kits
US9102948B2 (en) 2006-11-17 2015-08-11 22Nd Century Limited, Llc Regulating alkaloids
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US9127312B2 (en) 2011-02-09 2015-09-08 Bio-Rad Laboratories, Inc. Analysis of nucleic acids
PT2403878T (pt) * 2009-03-05 2017-09-01 Squibb & Sons Llc Anticorpos completamente humanos específicos a cadm1
EP2504448B1 (de) * 2009-11-25 2016-10-19 Bio-Rad Laboratories, Inc. Verfahren und zusammensetzung zur erkennung von genetischem material
WO2013163428A1 (en) * 2012-04-25 2013-10-31 The Regents Of The University Of Colorado Detection of ret fusions in cancer
JP7190165B2 (ja) * 2018-04-13 2022-12-15 学校法人近畿大学 慢性腎臓病罹患の可能性の判定のための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6251594B1 (en) 1997-06-09 2001-06-26 Usc/Norris Comprehensive Cancer Ctr. Cancer diagnostic method based upon DNA methylation differences
EP1102848B1 (de) * 1998-08-07 2010-10-13 Immunex Corporation Ldcam genannte moleküle
JP2002530062A (ja) * 1998-10-28 2002-09-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １２個のヒト分泌タンパク質
WO2000028032A2 (en) * 1998-11-12 2000-05-18 Incyte Pharmaceuticals, Inc. Human cell surface receptor proteins
DE60136212D1 (de) * 2000-08-15 2008-11-27 Univ Johns Hopkins Med Diagnose und behandlung von tumor-suppressor assoziierten krankheiten

Also Published As

Publication number Publication date
US20070072224A1 (en) 2007-03-29
CA2419529C (en) 2013-02-12
US6596493B1 (en) 2003-07-22
CA2419529A1 (en) 2002-02-21
EP1339871B1 (de) 2008-10-15
WO2002014557A1 (en) 2002-02-21
US7833712B2 (en) 2010-11-16
EP1339871A1 (de) 2003-09-03
DE60136212D1 (de) 2008-11-27
AU2001286514A1 (en) 2002-02-25
US7153657B2 (en) 2006-12-26
EP1339871A4 (de) 2005-08-17
US20030165974A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
Ribero et al. Effect of age on melanoma risk, prognosis and treatment response
ATE411037T1 (de) Diagnose und behandlung von tumor-suppressor assoziierten krankheiten
Wang et al. Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming
ES2964607T3 (es) Silenciamiento epigenético de NMT2
McKenzie et al. Role of the apoptotic and mitotic regulator survivin in melanoma
Takenoue et al. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
Ceccarelli et al. The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants
Catalano et al. Epigenetics modifications and therapeutic prospects in human thyroid cancer
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
Maury et al. Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
WO2007112330A3 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
WO2005024603A3 (en) Methods for detecting, diagnosing and treating human renal cell carcinoma
TW200639165A (en) Certain substituted ureas as modulators of kinase activity
WO2007092414A8 (en) Use of phosphatases to treat tumors overexpressing n-cor
WO2007024294A3 (en) Certain substituted ureas, as modulators of kinase activity
JP2013525283A5 (de)
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
Furukawa et al. PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
Melosky Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer
ATE175996T1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
Qiu et al. HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
Flitney et al. Antitumor actions of ruthenium (III)-based nitric oxide scavengers and nitric oxide synthase inhibitors
Ades et al. Targeting the cellular signaling: BRAF inhibition and beyond for the treatment of metastatic malignant melanoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties